APO Research
Talk to an analyst

APO RESEARCH · REPORT

Medicine for Osteoarthritis Pain

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Medicine for Osteoarthritis Pain Market Analysis and Forecast 2026-2032

21 December 2025205 pages

Choose your research edition.

Industry ResearchMedicine for Osteoarthritis Pain Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Medicine for Osteoarthritis Pain Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Medicine for Osteoarthritis Pain Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medicine for Osteoarthritis Pain Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Medicine for Osteoarthritis Pain Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Medicine for Osteoarthritis Pain market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Medicine for Osteoarthritis Pain is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Medicine for Osteoarthritis Pain is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Medicine for Osteoarthritis Pain is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Medicine for Osteoarthritis Pain is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Medicine for Osteoarthritis Pain include Abbott, TEVA, Sanofi, Johnson and Johnson, Novartis, Mylan, Eli Lilly, Hengrui Pharmaceutical and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Medicine for Osteoarthritis Pain, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Medicine for Osteoarthritis Pain, also provides the sales of main regions and countries. Of the upcoming market potential for Medicine for Osteoarthritis Pain, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Medicine for Osteoarthritis Pain sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Medicine for Osteoarthritis Pain market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Medicine for Osteoarthritis Pain sales, projected growth trends, production technology, application and end-user industry.

Medicine for Osteoarthritis Pain Segment by Company

Abbott

TEVA

Sanofi

Johnson and Johnson

Novartis

Mylan

Eli Lilly

Hengrui Pharmaceutical

Pfizer

GlaxoSmithKline

Daiichi Sankyo

Bayer

Tide Pharmaceutical

Iroko Pharmaceuticals

Horizon Pharma

Astellas Pharma

Almatica Pharma

Abiogen Pharma

Medicine for Osteoarthritis Pain Segment by Type

Injection

External

Oral

Medicine for Osteoarthritis Pain Segment by Application

Medical Care

Personal Care

Medicine for Osteoarthritis Pain Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medicine for Osteoarthritis Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medicine for Osteoarthritis Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medicine for Osteoarthritis Pain.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Medicine for Osteoarthritis Pain in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Medicine for Osteoarthritis Pain manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Medicine for Osteoarthritis Pain sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Medicine for Osteoarthritis Pain Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injection Major Manufacturers Table 3. External Major Manufacturers Table 4. Oral Major Manufacturers Table 5. Global Medicine for Osteoarthritis Pain Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Medical Care Major Manufacturers Table 7. Personal Care Major Manufacturers Table 8. Medicine for Osteoarthritis Pain Industry Trends Table 9. Medicine for Osteoarthritis Pain Industry Drivers Table 10. Medicine for Osteoarthritis Pain Industry Opportunities and Challenges Table 11. Medicine for Osteoarthritis Pain Industry Restraints Table 12. Global Medicine for Osteoarthritis Pain Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Medicine for Osteoarthritis Pain Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Medicine for Osteoarthritis Pain Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Medicine for Osteoarthritis Pain Revenue Market Share by Region (2021-2026) Table 16. Global Medicine for Osteoarthritis Pain Revenue Market Share by Region (2027-2032) Table 17. Global Medicine for Osteoarthritis Pain Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 18. Global Medicine for Osteoarthritis Pain Sales by Region (2021-2026) & (k units) Table 19. Global Medicine for Osteoarthritis Pain Sales by Region (2027-2032) & (k units) Table 20. Global Medicine for Osteoarthritis Pain Sales Market Share by Region (2021-2026) Table 21. Global Medicine for Osteoarthritis Pain Sales Market Share by Region (2027-2032) Table 22. Global Medicine for Osteoarthritis Pain Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Medicine for Osteoarthritis Pain Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Medicine for Osteoarthritis Pain Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Medicine for Osteoarthritis Pain Sales Market Share by Manufacturers (2021-2026) Table 26. Global Medicine for Osteoarthritis Pain Sales Price (US$/unit) of Manufacturers (2021-2026) Table 27. Global Medicine for Osteoarthritis Pain Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Medicine for Osteoarthritis Pain Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Medicine for Osteoarthritis Pain Manufacturers, Product Type & Application Table 30. Global Medicine for Osteoarthritis Pain Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Medicine for Osteoarthritis Pain by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Medicine for Osteoarthritis Pain Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Medicine for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Medicine for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2021-2026) Table 37. Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2027-2032) Table 38. Global Medicine for Osteoarthritis Pain Sales by Type 2021 VS 2025 VS 2032 (k units) Table 39. Global Medicine for Osteoarthritis Pain Sales by Type (2021-2026) & (k units) Table 40. Global Medicine for Osteoarthritis Pain Sales by Type (2027-2032) & (k units) Table 41. Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2021-2026) Table 42. Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2027-2032) Table 43. Global Medicine for Osteoarthritis Pain Price by Type (2021-2026) & (US$/unit) Table 44. Global Medicine for Osteoarthritis Pain Price by Type (2027-2032) & (US$/unit) Table 45. Global Medicine for Osteoarthritis Pain Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Medicine for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Medicine for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2021-2026) Table 49. Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2027-2032) Table 50. Global Medicine for Osteoarthritis Pain Sales by Application 2021 VS 2025 VS 2032 (k units) Table 51. Global Medicine for Osteoarthritis Pain Sales by Application (2021-2026) & (k units) Table 52. Global Medicine for Osteoarthritis Pain Sales by Application (2027-2032) & (k units) Table 53. Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2021-2026) Table 54. Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2027-2032) Table 55. Global Medicine for Osteoarthritis Pain Price by Application (2021-2026) & (US$/unit) Table 56. Global Medicine for Osteoarthritis Pain Price by Application (2027-2032) & (US$/unit) Table 57. Abbott Company Information Table 58. Abbott Business Overview Table 59. Abbott Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 60. Abbott Medicine for Osteoarthritis Pain Product Portfolio Table 61. Abbott Recent Development Table 62. TEVA Company Information Table 63. TEVA Business Overview Table 64. TEVA Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. TEVA Medicine for Osteoarthritis Pain Product Portfolio Table 66. TEVA Recent Development Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Sanofi Medicine for Osteoarthritis Pain Product Portfolio Table 71. Sanofi Recent Development Table 72. Johnson and Johnson Company Information Table 73. Johnson and Johnson Business Overview Table 74. Johnson and Johnson Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Johnson and Johnson Medicine for Osteoarthritis Pain Product Portfolio Table 76. Johnson and Johnson Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Novartis Medicine for Osteoarthritis Pain Product Portfolio Table 81. Novartis Recent Development Table 82. Mylan Company Information Table 83. Mylan Business Overview Table 84. Mylan Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Mylan Medicine for Osteoarthritis Pain Product Portfolio Table 86. Mylan Recent Development Table 87. Eli Lilly Company Information Table 88. Eli Lilly Business Overview Table 89. Eli Lilly Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Eli Lilly Medicine for Osteoarthritis Pain Product Portfolio Table 91. Eli Lilly Recent Development Table 92. Hengrui Pharmaceutical Company Information Table 93. Hengrui Pharmaceutical Business Overview Table 94. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio Table 96. Hengrui Pharmaceutical Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Pfizer Medicine for Osteoarthritis Pain Product Portfolio Table 101. Pfizer Recent Development Table 102. GlaxoSmithKline Company Information Table 103. GlaxoSmithKline Business Overview Table 104. GlaxoSmithKline Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. GlaxoSmithKline Medicine for Osteoarthritis Pain Product Portfolio Table 106. GlaxoSmithKline Recent Development Table 107. Daiichi Sankyo Company Information Table 108. Daiichi Sankyo Business Overview Table 109. Daiichi Sankyo Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Daiichi Sankyo Medicine for Osteoarthritis Pain Product Portfolio Table 111. Daiichi Sankyo Recent Development Table 112. Bayer Company Information Table 113. Bayer Business Overview Table 114. Bayer Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Bayer Medicine for Osteoarthritis Pain Product Portfolio Table 116. Bayer Recent Development Table 117. Tide Pharmaceutical Company Information Table 118. Tide Pharmaceutical Business Overview Table 119. Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Tide Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio Table 121. Tide Pharmaceutical Recent Development Table 122. Iroko Pharmaceuticals Company Information Table 123. Iroko Pharmaceuticals Business Overview Table 124. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Product Portfolio Table 126. Iroko Pharmaceuticals Recent Development Table 127. Horizon Pharma Company Information Table 128. Horizon Pharma Business Overview Table 129. Horizon Pharma Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Horizon Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 131. Horizon Pharma Recent Development Table 132. Astellas Pharma Company Information Table 133. Astellas Pharma Business Overview Table 134. Astellas Pharma Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Astellas Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 136. Astellas Pharma Recent Development Table 137. Almatica Pharma Company Information Table 138. Almatica Pharma Business Overview Table 139. Almatica Pharma Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 140. Almatica Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 141. Almatica Pharma Recent Development Table 142. Abiogen Pharma Company Information Table 143. Abiogen Pharma Business Overview Table 144. Abiogen Pharma Medicine for Osteoarthritis Pain Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 145. Abiogen Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 146. Abiogen Pharma Recent Development Table 147. North America Medicine for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 148. North America Medicine for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 149. North America Medicine for Osteoarthritis Pain Sales by Type (2021-2026) & (k units) Table 150. North America Medicine for Osteoarthritis Pain Sales by Type (2027-2032) & (k units) Table 151. North America Medicine for Osteoarthritis Pain Sales Price by Type (2021-2026) & (US$/unit) Table 152. North America Medicine for Osteoarthritis Pain Sales Price by Type (2027-2032) & (US$/unit) Table 153. North America Medicine for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Medicine for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Medicine for Osteoarthritis Pain Sales by Application (2021-2026) & (k units) Table 156. North America Medicine for Osteoarthritis Pain Sales by Application (2027-2032) & (k units) Table 157. North America Medicine for Osteoarthritis Pain Sales Price by Application (2021-2026) & (US$/unit) Table 158. North America Medicine for Osteoarthritis Pain Sales Price by Application (2027-2032) & (US$/unit) Table 159. North America Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. North America Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. North America Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. North America Medicine for Osteoarthritis Pain Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 163. North America Medicine for Osteoarthritis Pain Sales by Country (2021-2026) & (k units) Table 164. North America Medicine for Osteoarthritis Pain Sales by Country (2027-2032) & (k units) Table 165. North America Medicine for Osteoarthritis Pain Sales Price by Country (2021-2026) & (US$/unit) Table 166. North America Medicine for Osteoarthritis Pain Sales Price by Country (2027-2032) & (US$/unit) Table 167. United States Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 168. Canada Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 169. Mexico Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 170. Europe Medicine for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 171. Europe Medicine for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 172. Europe Medicine for Osteoarthritis Pain Sales by Type (2021-2026) & (k units) Table 173. Europe Medicine for Osteoarthritis Pain Sales by Type (2027-2032) & (k units) Table 174. Europe Medicine for Osteoarthritis Pain Sales Price by Type (2021-2026) & (US$/unit) Table 175. Europe Medicine for Osteoarthritis Pain Sales Price by Type (2027-2032) & (US$/unit) Table 176. Europe Medicine for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 177. Europe Medicine for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 178. Europe Medicine for Osteoarthritis Pain Sales by Application (2021-2026) & (k units) Table 179. Europe Medicine for Osteoarthritis Pain Sales by Application (2027-2032) & (k units) Table 180. Europe Medicine for Osteoarthritis Pain Sales Price by Application (2021-2026) & (US$/unit) Table 181. Europe Medicine for Osteoarthritis Pain Sales Price by Application (2027-2032) & (US$/unit) Table 182. Europe Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. Europe Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. Europe Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. Europe Medicine for Osteoarthritis Pain Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 186. Europe Medicine for Osteoarthritis Pain Sales by Country (2021-2026) & (k units) Table 187. Europe Medicine for Osteoarthritis Pain Sales by Country (2027-2032) & (k units) Table 188. Europe Medicine for Osteoarthritis Pain Sales Price by Country (2021-2026) & (US$/unit) Table 189. Europe Medicine for Osteoarthritis Pain Sales Price by Country (2027-2032) & (US$/unit) Table 190. Germany Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 191. France Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 192. U.K. Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 193. Italy Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 194. Russia Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 195. Spain Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 196. Netherlands Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 197. Switzerland Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 198. Sweden Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 199. Poland Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 200. China Medicine for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 201. China Medicine for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 202. China Medicine for Osteoarthritis Pain Sales by Type (2021-2026) & (k units) Table 203. China Medicine for Osteoarthritis Pain Sales by Type (2027-2032) & (k units) Table 204. China Medicine for Osteoarthritis Pain Sales Price by Type (2021-2026) & (US$/unit) Table 205. China Medicine for Osteoarthritis Pain Sales Price by Type (2027-2032) & (US$/unit) Table 206. China Medicine for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 207. China Medicine for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 208. China Medicine for Osteoarthritis Pain Sales by Application (2021-2026) & (k units) Table 209. China Medicine for Osteoarthritis Pain Sales by Application (2027-2032) & (k units) Table 210. China Medicine for Osteoarthritis Pain Sales Price by Application (2021-2026) & (US$/unit) Table 211. China Medicine for Osteoarthritis Pain Sales Price by Application (2027-2032) & (US$/unit) Table 212. Asia Medicine for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 213. Asia Medicine for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 214. Asia Medicine for Osteoarthritis Pain Sales by Type (2021-2026) & (k units) Table 215. Asia Medicine for Osteoarthritis Pain Sales by Type (2027-2032) & (k units) Table 216. Asia Medicine for Osteoarthritis Pain Sales Price by Type (2021-2026) & (US$/unit) Table 217. Asia Medicine for Osteoarthritis Pain Sales Price by Type (2027-2032) & (US$/unit) Table 218. Asia Medicine for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 219. Asia Medicine for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 220. Asia Medicine for Osteoarthritis Pain Sales by Application (2021-2026) & (k units) Table 221. Asia Medicine for Osteoarthritis Pain Sales by Application (2027-2032) & (k units) Table 222. Asia Medicine for Osteoarthritis Pain Sales Price by Application (2021-2026) & (US$/unit) Table 223. Asia Medicine for Osteoarthritis Pain Sales Price by Application (2027-2032) & (US$/unit) Table 224. Asia Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 225. Asia Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 226. Asia Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 227. Asia Medicine for Osteoarthritis Pain Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 228. Asia Medicine for Osteoarthritis Pain Sales by Country (2021-2026) & (k units) Table 229. Asia Medicine for Osteoarthritis Pain Sales by Country (2027-2032) & (k units) Table 230. Asia Medicine for Osteoarthritis Pain Sales Price by Country (2021-2026) & (US$/unit) Table 231. Asia Medicine for Osteoarthritis Pain Sales Price by Country (2027-2032) & (US$/unit) Table 232. Japan Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 233. South Korea Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 234. India Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 235. Australia Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 236. Taiwan Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 237. Southeast Asia Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 238. SAMEA Medicine for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 239. SAMEA Medicine for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 240. SAMEA Medicine for Osteoarthritis Pain Sales by Type (2021-2026) & (k units) Table 241. SAMEA Medicine for Osteoarthritis Pain Sales by Type (2027-2032) & (k units) Table 242. SAMEA Medicine for Osteoarthritis Pain Sales Price by Type (2021-2026) & (US$/unit) Table 243. SAMEA Medicine for Osteoarthritis Pain Sales Price by Type (2027-2032) & (US$/unit) Table 244. SAMEA Medicine for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 245. SAMEA Medicine for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 246. SAMEA Medicine for Osteoarthritis Pain Sales by Application (2021-2026) & (k units) Table 247. SAMEA Medicine for Osteoarthritis Pain Sales by Application (2027-2032) & (k units) Table 248. SAMEA Medicine for Osteoarthritis Pain Sales Price by Application (2021-2026) & (US$/unit) Table 249. SAMEA Medicine for Osteoarthritis Pain Sales Price by Application (2027-2032) & (US$/unit) Table 250. SAMEA Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 251. SAMEA Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 252. SAMEA Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 253. SAMEA Medicine for Osteoarthritis Pain Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 254. SAMEA Medicine for Osteoarthritis Pain Sales by Country (2021-2026) & (k units) Table 255. SAMEA Medicine for Osteoarthritis Pain Sales by Country (2027-2032) & (k units) Table 256. SAMEA Medicine for Osteoarthritis Pain Sales Price by Country (2021-2026) & (US$/unit) Table 257. SAMEA Medicine for Osteoarthritis Pain Sales Price by Country (2027-2032) & (US$/unit) Table 258. Brazil Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 259. Argentina Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 260. Chile Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 261. Colombia Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 262. Peru Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 263. Saudi Arabia Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 264. Israel Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 265. UAE Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 266. Turkey Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 267. Iran Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 268. Egypt Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Table 269. Key Raw Materials Table 270. Raw Materials Key Suppliers Table 271. Medicine for Osteoarthritis Pain Distributors List Table 272. Medicine for Osteoarthritis Pain Customers List Table 273. Research Programs/Design for This Report Table 274. Authors List of This Report Table 275. Secondary Sources Table 276. Primary Sources List of Figures Figure 1. Medicine for Osteoarthritis Pain Image Figure 2. Global Medicine for Osteoarthritis Pain Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medicine for Osteoarthritis Pain Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injection Image Figure 5. External Image Figure 6. Oral Image Figure 7. Global Medicine for Osteoarthritis Pain Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Medicine for Osteoarthritis Pain Market Size Share 2021 VS 2025 VS 2032 Figure 9. Medical Care Image Figure 10. Personal Care Image Figure 11. Global Medicine for Osteoarthritis Pain Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Medicine for Osteoarthritis Pain Revenue (2021-2032) & (US$ Million) Figure 13. Global Medicine for Osteoarthritis Pain Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Medicine for Osteoarthritis Pain Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Medicine for Osteoarthritis Pain Revenue Market Share by Region (2021-2032) Figure 16. Global Medicine for Osteoarthritis Pain Sales (2021-2032) & (k units) Figure 17. Global Medicine for Osteoarthritis Pain Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 18. Global Medicine for Osteoarthritis Pain Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Medicine for Osteoarthritis Pain Sales YoY (2021-2032) & (k units) Figure 20. Europe Medicine for Osteoarthritis Pain Sales YoY (2021-2032) & (k units) Figure 21. China Medicine for Osteoarthritis Pain Sales YoY (2021-2032) & (k units) Figure 22. Asia (Excluding China) Medicine for Osteoarthritis Pain Sales YoY (2021-2032) & (k units) Figure 23. South America, Middle East and Africa Medicine for Osteoarthritis Pain Sales YoY (2021-2032) & (k units) Figure 24. Global Medicine for Osteoarthritis Pain Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Medicine for Osteoarthritis Pain Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Medicine for Osteoarthritis Pain Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Medicine for Osteoarthritis Pain Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2021-2032) Figure 30. Global Medicine for Osteoarthritis Pain Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 31. Global Medicine for Osteoarthritis Pain Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2021-2032) Figure 33. Global Medicine for Osteoarthritis Pain Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Medicine for Osteoarthritis Pain Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2021-2032) Figure 36. Global Medicine for Osteoarthritis Pain Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 37. Global Medicine for Osteoarthritis Pain Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2021-2032) Figure 39. North America Medicine for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 40. North America Medicine for Osteoarthritis Pain Sales Share by Type (2021-2032) Figure 41. North America Medicine for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 42. North America Medicine for Osteoarthritis Pain Sales Share by Application (2021-2032) Figure 43. North America Medicine for Osteoarthritis Pain Revenue Share by Country (2021-2032) Figure 44. North America Medicine for Osteoarthritis Pain Sales Share by Country (2021-2032) Figure 45. Europe Medicine for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 46. Europe Medicine for Osteoarthritis Pain Sales Share by Type (2021-2032) Figure 47. Europe Medicine for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 48. Europe Medicine for Osteoarthritis Pain Sales Share by Application (2021-2032) Figure 49. Europe Medicine for Osteoarthritis Pain Revenue Share by Country (2021-2032) Figure 50. Europe Medicine for Osteoarthritis Pain Sales Share by Country (2021-2032) Figure 51. China Medicine for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 52. China Medicine for Osteoarthritis Pain Sales Share by Type (2021-2032) Figure 53. China Medicine for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 54. China Medicine for Osteoarthritis Pain Sales Share by Application (2021-2032) Figure 55. Asia Medicine for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 56. Asia Medicine for Osteoarthritis Pain Sales Share by Type (2021-2032) Figure 57. Asia Medicine for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 58. Asia Medicine for Osteoarthritis Pain Sales Share by Application (2021-2032) Figure 59. Asia Medicine for Osteoarthritis Pain Revenue Share by Country (2021-2032) Figure 60. Asia Medicine for Osteoarthritis Pain Sales Share by Country (2021-2032) Figure 61. SAMEA Medicine for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 62. SAMEA Medicine for Osteoarthritis Pain Sales Share by Type (2021-2032) Figure 63. SAMEA Medicine for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 64. SAMEA Medicine for Osteoarthritis Pain Sales Share by Application (2021-2032) Figure 65. SAMEA Medicine for Osteoarthritis Pain Revenue Share by Country (2021-2032) Figure 66. SAMEA Medicine for Osteoarthritis Pain Sales Share by Country (2021-2032) Figure 67. Medicine for Osteoarthritis Pain Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Medicine for Osteoarthritis Pain Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • External
  • Oral
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Abbott
  • TEVA
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Mylan
  • Eli Lilly
  • Hengrui Pharmaceutical
  • Pfizer
  • GlaxoSmithKline
  • Daiichi Sankyo
  • Bayer
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Horizon Pharma
  • Astellas Pharma
  • Almatica Pharma
  • Abiogen Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Medicine for Osteoarthritis Pain Market by Type
  3. 1.2.1 Global Medicine for Osteoarthritis Pain Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injection
  5. 1.2.3 External
  6. 1.2.4 Oral
  7. 1.3 Medicine for Osteoarthritis Pain Market by Application
  8. 1.3.1 Global Medicine for Osteoarthritis Pain Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Medical Care
  10. 1.3.3 Personal Care
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Medicine for Osteoarthritis Pain Market Dynamics
  1. 2.1 Medicine for Osteoarthritis Pain Industry Trends
  2. 2.2 Medicine for Osteoarthritis Pain Industry Drivers
  3. 2.3 Medicine for Osteoarthritis Pain Industry Opportunities and Challenges
  4. 2.4 Medicine for Osteoarthritis Pain Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Medicine for Osteoarthritis Pain Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Medicine for Osteoarthritis Pain Revenue by Region
  3. 3.2.1 Global Medicine for Osteoarthritis Pain Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Medicine for Osteoarthritis Pain Revenue by Region (2021-2026)
  5. 3.2.3 Global Medicine for Osteoarthritis Pain Revenue by Region (2027-2032)
  6. 3.2.4 Global Medicine for Osteoarthritis Pain Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Medicine for Osteoarthritis Pain Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Medicine for Osteoarthritis Pain Sales by Region
  9. 3.4.1 Global Medicine for Osteoarthritis Pain Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Medicine for Osteoarthritis Pain Sales by Region (2021-2026)
  11. 3.4.3 Global Medicine for Osteoarthritis Pain Sales by Region (2027-2032)
  12. 3.4.4 Global Medicine for Osteoarthritis Pain Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Medicine for Osteoarthritis Pain Revenue by Manufacturers
  2. 4.1.1 Global Medicine for Osteoarthritis Pain Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Medicine for Osteoarthritis Pain Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Medicine for Osteoarthritis Pain Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Medicine for Osteoarthritis Pain Sales by Manufacturers
  6. 4.2.1 Global Medicine for Osteoarthritis Pain Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Medicine for Osteoarthritis Pain Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Medicine for Osteoarthritis Pain Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Medicine for Osteoarthritis Pain Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Medicine for Osteoarthritis Pain Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Medicine for Osteoarthritis Pain Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Medicine for Osteoarthritis Pain Manufacturers, Product Type & Application
  13. 4.7 Global Medicine for Osteoarthritis Pain Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Medicine for Osteoarthritis Pain Market CR5 and HHI
  16. 4.8.2 2025 Medicine for Osteoarthritis Pain Tier 1, Tier 2, and Tier 3
5 Medicine for Osteoarthritis Pain Market by Type
  1. 5.1 Global Medicine for Osteoarthritis Pain Revenue by Type
  2. 5.1.1 Global Medicine for Osteoarthritis Pain Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Medicine for Osteoarthritis Pain Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Medicine for Osteoarthritis Pain Sales by Type
  6. 5.2.1 Global Medicine for Osteoarthritis Pain Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Medicine for Osteoarthritis Pain Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2021-2032)
  9. 5.3 Global Medicine for Osteoarthritis Pain Price by Type
6 Medicine for Osteoarthritis Pain Market by Application
  1. 6.1 Global Medicine for Osteoarthritis Pain Revenue by Application
  2. 6.1.1 Global Medicine for Osteoarthritis Pain Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Medicine for Osteoarthritis Pain Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Medicine for Osteoarthritis Pain Sales by Application
  6. 6.2.1 Global Medicine for Osteoarthritis Pain Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Medicine for Osteoarthritis Pain Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2021-2032)
  9. 6.3 Global Medicine for Osteoarthritis Pain Price by Application
7 Company Profiles
  1. 7.1 Abbott
  2. 7.1.1 Abbott Company Information
  3. 7.1.2 Abbott Business Overview
  4. 7.1.3 Abbott Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Medicine for Osteoarthritis Pain Product Portfolio
  6. 7.1.5 Abbott Recent Developments
  7. 7.2 TEVA
  8. 7.2.1 TEVA Company Information
  9. 7.2.2 TEVA Business Overview
  10. 7.2.3 TEVA Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 TEVA Medicine for Osteoarthritis Pain Product Portfolio
  12. 7.2.5 TEVA Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Medicine for Osteoarthritis Pain Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Johnson and Johnson
  20. 7.4.1 Johnson and Johnson Company Information
  21. 7.4.2 Johnson and Johnson Business Overview
  22. 7.4.3 Johnson and Johnson Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Johnson and Johnson Medicine for Osteoarthritis Pain Product Portfolio
  24. 7.4.5 Johnson and Johnson Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Medicine for Osteoarthritis Pain Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Mylan
  32. 7.6.1 Mylan Company Information
  33. 7.6.2 Mylan Business Overview
  34. 7.6.3 Mylan Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Mylan Medicine for Osteoarthritis Pain Product Portfolio
  36. 7.6.5 Mylan Recent Developments
  37. 7.7 Eli Lilly
  38. 7.7.1 Eli Lilly Company Information
  39. 7.7.2 Eli Lilly Business Overview
  40. 7.7.3 Eli Lilly Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly Medicine for Osteoarthritis Pain Product Portfolio
  42. 7.7.5 Eli Lilly Recent Developments
  43. 7.8 Hengrui Pharmaceutical
  44. 7.8.1 Hengrui Pharmaceutical Company Information
  45. 7.8.2 Hengrui Pharmaceutical Business Overview
  46. 7.8.3 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio
  48. 7.8.5 Hengrui Pharmaceutical Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Medicine for Osteoarthritis Pain Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 GlaxoSmithKline
  56. 7.10.1 GlaxoSmithKline Company Information
  57. 7.10.2 GlaxoSmithKline Business Overview
  58. 7.10.3 GlaxoSmithKline Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 GlaxoSmithKline Medicine for Osteoarthritis Pain Product Portfolio
  60. 7.10.5 GlaxoSmithKline Recent Developments
  61. 7.11 Daiichi Sankyo
  62. 7.11.1 Daiichi Sankyo Company Information
  63. 7.11.2 Daiichi Sankyo Business Overview
  64. 7.11.3 Daiichi Sankyo Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Daiichi Sankyo Medicine for Osteoarthritis Pain Product Portfolio
  66. 7.11.5 Daiichi Sankyo Recent Developments
  67. 7.12 Bayer
  68. 7.12.1 Bayer Company Information
  69. 7.12.2 Bayer Business Overview
  70. 7.12.3 Bayer Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Bayer Medicine for Osteoarthritis Pain Product Portfolio
  72. 7.12.5 Bayer Recent Developments
  73. 7.13 Tide Pharmaceutical
  74. 7.13.1 Tide Pharmaceutical Company Information
  75. 7.13.2 Tide Pharmaceutical Business Overview
  76. 7.13.3 Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Tide Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio
  78. 7.13.5 Tide Pharmaceutical Recent Developments
  79. 7.14 Iroko Pharmaceuticals
  80. 7.14.1 Iroko Pharmaceuticals Company Information
  81. 7.14.2 Iroko Pharmaceuticals Business Overview
  82. 7.14.3 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Product Portfolio
  84. 7.14.5 Iroko Pharmaceuticals Recent Developments
  85. 7.15 Horizon Pharma
  86. 7.15.1 Horizon Pharma Company Information
  87. 7.15.2 Horizon Pharma Business Overview
  88. 7.15.3 Horizon Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Horizon Pharma Medicine for Osteoarthritis Pain Product Portfolio
  90. 7.15.5 Horizon Pharma Recent Developments
  91. 7.16 Astellas Pharma
  92. 7.16.1 Astellas Pharma Company Information
  93. 7.16.2 Astellas Pharma Business Overview
  94. 7.16.3 Astellas Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Astellas Pharma Medicine for Osteoarthritis Pain Product Portfolio
  96. 7.16.5 Astellas Pharma Recent Developments
  97. 7.17 Almatica Pharma
  98. 7.17.1 Almatica Pharma Company Information
  99. 7.17.2 Almatica Pharma Business Overview
  100. 7.17.3 Almatica Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Almatica Pharma Medicine for Osteoarthritis Pain Product Portfolio
  102. 7.17.5 Almatica Pharma Recent Developments
  103. 7.18 Abiogen Pharma
  104. 7.18.1 Abiogen Pharma Company Information
  105. 7.18.2 Abiogen Pharma Business Overview
  106. 7.18.3 Abiogen Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Abiogen Pharma Medicine for Osteoarthritis Pain Product Portfolio
  108. 7.18.5 Abiogen Pharma Recent Developments
8 North America
  1. 8.1 North America Medicine for Osteoarthritis Pain Market Size by Type
  2. 8.1.1 North America Medicine for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 8.1.2 North America Medicine for Osteoarthritis Pain Sales by Type (2021-2032)
  4. 8.1.3 North America Medicine for Osteoarthritis Pain Price by Type (2021-2032)
  5. 8.2 North America Medicine for Osteoarthritis Pain Market Size by Application
  6. 8.2.1 North America Medicine for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 8.2.2 North America Medicine for Osteoarthritis Pain Sales by Application (2021-2032)
  8. 8.2.3 North America Medicine for Osteoarthritis Pain Price by Application (2021-2032)
  9. 8.3 North America Medicine for Osteoarthritis Pain Market Size by Country
  10. 8.3.1 North America Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Medicine for Osteoarthritis Pain Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Medicine for Osteoarthritis Pain Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Medicine for Osteoarthritis Pain Market Size by Type
  2. 9.1.1 Europe Medicine for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 9.1.2 Europe Medicine for Osteoarthritis Pain Sales by Type (2021-2032)
  4. 9.1.3 Europe Medicine for Osteoarthritis Pain Price by Type (2021-2032)
  5. 9.2 Europe Medicine for Osteoarthritis Pain Market Size by Application
  6. 9.2.1 Europe Medicine for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 9.2.2 Europe Medicine for Osteoarthritis Pain Sales by Application (2021-2032)
  8. 9.2.3 Europe Medicine for Osteoarthritis Pain Price by Application (2021-2032)
  9. 9.3 Europe Medicine for Osteoarthritis Pain Market Size by Country
  10. 9.3.1 Europe Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Medicine for Osteoarthritis Pain Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Medicine for Osteoarthritis Pain Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Medicine for Osteoarthritis Pain Market Size by Type
  2. 10.1.1 China Medicine for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 10.1.2 China Medicine for Osteoarthritis Pain Sales by Type (2021-2032)
  4. 10.1.3 China Medicine for Osteoarthritis Pain Price by Type (2021-2032)
  5. 10.2 China Medicine for Osteoarthritis Pain Market Size by Application
  6. 10.2.1 China Medicine for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 10.2.2 China Medicine for Osteoarthritis Pain Sales by Application (2021-2032)
  8. 10.2.3 China Medicine for Osteoarthritis Pain Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Medicine for Osteoarthritis Pain Market Size by Type
  2. 11.1.1 Asia Medicine for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 11.1.2 Asia Medicine for Osteoarthritis Pain Sales by Type (2021-2032)
  4. 11.1.3 Asia Medicine for Osteoarthritis Pain Price by Type (2021-2032)
  5. 11.2 Asia Medicine for Osteoarthritis Pain Market Size by Application
  6. 11.2.1 Asia Medicine for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 11.2.2 Asia Medicine for Osteoarthritis Pain Sales by Application (2021-2032)
  8. 11.2.3 Asia Medicine for Osteoarthritis Pain Price by Application (2021-2032)
  9. 11.3 Asia Medicine for Osteoarthritis Pain Market Size by Country
  10. 11.3.1 Asia Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Medicine for Osteoarthritis Pain Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Medicine for Osteoarthritis Pain Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Medicine for Osteoarthritis Pain Market Size by Type
  2. 12.1.1 SAMEA Medicine for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Medicine for Osteoarthritis Pain Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Medicine for Osteoarthritis Pain Price by Type (2021-2032)
  5. 12.2 SAMEA Medicine for Osteoarthritis Pain Market Size by Application
  6. 12.2.1 SAMEA Medicine for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Medicine for Osteoarthritis Pain Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Medicine for Osteoarthritis Pain Price by Application (2021-2032)
  9. 12.3 SAMEA Medicine for Osteoarthritis Pain Market Size by Country
  10. 12.3.1 SAMEA Medicine for Osteoarthritis Pain Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Medicine for Osteoarthritis Pain Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Medicine for Osteoarthritis Pain Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Medicine for Osteoarthritis Pain Value Chain Analysis
  2. 13.1.1 Medicine for Osteoarthritis Pain Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Medicine for Osteoarthritis Pain Production Mode & Process
  6. 13.2 Medicine for Osteoarthritis Pain Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Medicine for Osteoarthritis Pain Distributors
  9. 13.2.3 Medicine for Osteoarthritis Pain Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst